In conclusion, our data showed that patients with newly diagnosed T2D may take advantage of the metformin add-on CSII therapy in requiring less insulin doses, and having available other methods of glycemic treatments in a hospital setting. This evidence concerns the gene INS and type 2 diabetes mellitus.